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Abstract
Background: Dengue fever is rapidly expanding geographically, with about half of the world’s population now at
risk. Among the various diagnostic options, rapid diagnostic tests (RDTs) are convenient and prompt, but limited in
terms of accuracy and availability.
Methods: A systematic review was conducted of published data on the use of RDTs for dengue with respect to their
economic impact. The search was conducted with combinations of key search terms, including “((Dengue[Title]) AND
cost/economic)” and “rapid diagnostic test/assay (or point-of-care)”. Articles with insufficient report on cost/economic
aspect of dengue RDTs, usually on comparison of different RDTs or assessment of novel rapid diagnostic tools, were
excluded. This review has been registered in the PROSPERO International prospective register of systematic reviews
(registry #: CRD42015017775).
Results: Eleven articles were found through advanced search on Pubmed. From Embase and Web of Science, two and
14 articles were obtained, respectively. After removal of duplicate items, title screening was done on 21 published
works and 12 titles, including 2 meeting abstracts, were selected for abstract review. For full-text review, by two
independent reviewers, 5 articles and 1 meeting abstract were selected. Among these, the abstract was referring to the
same study results as one of the articles. After full text review, two studies (two articles and one abstract) were found
to report on cost-wise or economic benefits of dengue RDTs and were selected for data extraction. One study found
satisfactory performance of IgM-based Panbio RDT, concluding that it would be cost-effective in endemic settings. The
second study was a modeling analysis and showed that a dengue RDT would not be advantageous in terms of cost
and effectiveness compared to current practice of antibiotics prescription for acute febrile illness.
Conclusions: Despite growing use of RDTs in research and clinical settings, there were limited data to demonstrate an
economic impact. The available two studies reached different conclusions on the cost-effectiveness of dengue RDTs,
although only one of the two studies reported outcomes from cost-effectiveness analysis of dengue and the other was
considering febrile illness more generally. Evidence of such an impact would require further quantitative economic
studies.
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Background
Dengue fever, a mosquito-borne flavivirus infection caused
by four related but antigenically distinct dengue viruses
(DENVs, serotypes 1–4), is a major and rapidly increasing
public health problem. Its geographic range now includes
about half of the world’s population and continues to
expand, with epidemics that disrupt health care systems
[1–4]. Current WHO estimates are of about 50–100 million
annual infections globally, while Bhatt et al. recently
estimated 390 million infections annually with 96 million
disease episodes [5–7].
However, there are no other suitable disease prevention
methods: mosquito vector control is often ineffective [8,
9]. There is a vaccine, Sanofi Pasteur’s live attenuated
Dengvaxia®, recently registered in multiple countries in
Southeast Asia and Latin America and it shows to have
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variable efficacy [10–13]. At present, there are no drugs
for specific treatment and there is a need for accurate and
cheap dengue diagnostic tests to be widely used in clinical
settings [14–16]. Thus, many dengue endemic countries
in the tropics are still experiencing a rise in cases and in
deaths due to dengue [17–20].
Recently the WHO Strategic Advisory Group of Experts
(SAGE) on Immunization emphasized the need for estima-
tion of the true burden of dengue disease, including cost of
illness [6]. Data are available, but mostly focused in coun-
tries in Asia and Latin America, with well-documented
hyper-endemicity and a long history of dengue transmis-
sion, such as Thailand [21, 22], the Philippines [23], Brazil
[24, 25], Mexico [26], and Colombia [27]. Most of the avail-
able burden data are from studies of the epidemiology and
evidence based on economic studies is limited [28, 29].
Among the key limitations of economic studies of den-
gue are the challenges in its diagnosis. Often, cost-related
studies for dengue are based on clinical, rather than labora-
tory, confirmation [30]. Available methods include virus
isolation, serology, and molecular methods [31]. One test
routinely used by research laboratories for virus identifica-
tion is Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR) assay [32]. While this is a definite proof of infec-
tion and confirms the serotype, commercial kits that in-
clude serotyping are often expensive and would require
serum samples collected in early phase during the illness
[33]. Another commonly used method is immunoglobulin
type M (IgM) antibody capture enzyme-linked immuno-
sorbent assay (MAC-ELISA) [31]. With IgM staying
elevated for 2 to 3 months, interpretation could be challen-
ging given that elevated IgM could be due either to recent
past infection or to cross-reactivity with other flaviviruses
[33]. Any clinical management decision reached on the
basis of a single blood sample collected in the acute phase
is not conclusive. Levels of immunoglobulin type G (IgG)
stay elevated for months to years, so a positive result on
one of the available assays could indicate a past infection,
thus has limited implications for clinical management [31].
Moreover, it may cross-react across the Flavivirus group
(dengue virus, Japanese encephalitis virus, West Nile virus,
yellow fever virus, Zika virus, etc.) [34]. There are other as-
says such as Plaque Reduction Neutralization Test (PRNT)
which detect serotype-specific antibodies [35]. Compared
to others mentioned, these are time-consuming and
labour-intensive, thus expensive [36, 37].
Amongst different diagnostic tools, rapid diagnostic
tests (RDTs) are a convenient (easy to use) and prompt
option, despite their limitations in terms of accuracy [38].
While their availability could be limited, especially in
resource-limited settings, RDTs are commonly used for
dengue detection in many endemic countries [38]. There
could be a number of different commercially available
tests and they could be based on the detection of dengue
virus non-structural protein 1 (NS1) antigen, IgM, IgG, and
IgA antibodies [39]. Often, these tests have high specificity
(usually around 90%), but lower levels of sensitivity, ranging
from 10 to 99%, in detection of dengue and could be cross-
reactive with other flaviviruses [39–42]. However, the speed
of RDTs provides early diagnosis of dengue possibly leading
to timely case management. Given their limited accuracy,
these RDTs are not considered the standard reference and
their usefulness is not yet proven in clinical settings [15,
43]. However, some literature supports the use of such tests
in combination with others, for example the combined test
with NS1 antigen and IgM antibody [42, 44].
Especially in terms of economic studies, one major
benefit of using RDTs would be that they allow dengue
detection in the early phase of illness (at presentation),
hence facilitating capture of the entire spectrum of costs
incurred throughout illness. Previous studies reported
that early detection is effective in reducing the duration
of illness, possibly leading to lower cost-of-illness due to
dengue [45, 46]. In recognition of the need to balance
speed, accuracy, and availability to maximize utility
when using RDTs for dengue detection for the patients
in clinical settings, a systematic review was performed to
explore the economic impact of using RDTs for dengue.
The hypothesis behind this review was that there may be
economic impact due to prompt detection of dengue in
the early phase of illness using RDTs and economic im-
pact is defined to be broad: both from the point of view
of cost-effectiveness and from the perspective of finan-
cial impact of RDT in patients, i.e. early diagnosis pos-
sibly leading to cost-saving in patients.
Methods
In this review, literature published in English up to
September 2017 was covered. Scientific databases used for
the search were: Embase, IBSS, Medline (including
PubMed), and Web of Science. In order to take more cau-
tion and not miss articles that may imply on economic
benefit of RDTs, the literature search was conducted in a
comprehensive approach. In Pubmed, advance search was
performed with search terms “((Dengue[Title]) AND
cost)” OR “((Dengue[Title]) AND economic)” AND:
1. “rapid diagnostic test[MeSH Terms]”
2. “RDT[MeSH Terms]”
3. “rapid test[MeSH Terms]”
4. “rapid assay[MeSH Terms]”
5. “rapid diagnostic assay[MeSH Terms]”
6. “point-of-care [MeSH Terms]”
7. “POC[MeSH Terms]”
8. “point-of-care test[MeSH Terms]”
MeSH terms are assigned by indexers of the National
Library of Medicine [47]. While the search on Pubmed
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was performed with above search terms with “rapid diag-
nostic test” and “point-of-care test” were used as MeSH
terms, additional articles were identified through IBSS,
EMBASE, and Web of Science via general search using
keywords:
1. “dengue and rapid diagnostic test (or RDT) and cost”
2. “dengue and rapid diagnostic test (or RDT) and
economic”
3. “dengue and point-of-care (or POC) and cost”
4. “dengue and point-of-care (or POC) and economic”.
From Embase, Web of Science, and WHOLIS, outcomes
of general search included meeting abstracts in addition
to full articles. Preliminary screening needed to be done
for search outcomes through Embase and Web of Science,
as their general search led to journals, not articles, where
each key word may appear in different articles.
After such preliminary screening was done for search
outcomes through Embase and Web of Science, title
screening, abstract review, and full-text review were done.
The development of this literature review is shown in the
flow chart (Fig. 1). Rationales for excluding articles obtained
through this multiple searches using different sources were
described in Fig. 1. Exclusion criteria were not relevant
articles that:
– mainly report on cost associated with a new diagnostic
technology
– report on different technologies or performance of
the tests without addressing cost or economic aspect
of RDT use
– report on RDT-confirmed dengue case numbers in a
study with insufficient information on economic
impact
Also included for full-text review were those describing,
in addition to those with direct reporting of quantitative
costs, some qualitative economic benefit, i.e. mention of
cost-effectiveness of RDTs without any quantitative valu-
ation of it. This was done to prevent loss of any articles
containing cost-related implication, even if not quantita-
tively specified in the article. Data were then extracted
from the full texts of the selected articles. The data extrac-
tion table was developed following the Consolidated
Health Economic Evaluation Reporting Standards
(CHEERS) statement and the reporting Checklist [48].
Also, the reporting Checklist for Cost-effectiveness Ana-
lyses from Second Panel on Cost-Effectiveness in Health
and Medicine (Additional file 1: Table S1) [48, 49]. In
addition, the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) were followed [48,
50]. This review is registered in the PROSPERO inter-
national prospective register of systematic reviews, under
the title “Systematic review of health economic assess-
ments of dengue rapid diagnostic tests” (registry number:
CRD42015017775). Full text review was performed inde-
pendently by two individuals.
Results
As shown in Fig. 1, a more focused advanced search on
Pubmed resulted in 11 articles and, after preliminary
screening of the outcomes of general search on EMBASE
and Web of Science, there were 15 published works (2
articles from EMBASE and 14 titles from Web of Science
with one in overlap). After removal of duplicative articles,
21 titles from all three sources underwent screening. For
abstract review, 10 articles and 2 meeting abstracts were
considered relevant and among these 5 articles were
selected for full-text review and 1 meeting abstract was
retained and, as an abstract, skipped the full-text review
step.
On review of the full text of the articles, it was found that
only two studies reported quantitative or qualitative
economic impact of RDT use for dengue: one by Lubell et
al. and another by Mitra et al. The second study was
reported in an abstract and an article, the former being
published first [51, 52]. As the abstract was referring to the
same study results as the articles, they were merged in the
data extraction stage and were presented as one combined
piece of work. Some others found with “cost” or
“economic” as one of the key search terms and reached the
full-text review stage were proven to contain information
on the cost aspects of dengue RDTs. However, some were
found to report on the actual price of the test or cost of
production of a new assay as they assess performance of it.
The extracted data and findings from these two studies are
included in Additional file 1: Tables S1, 2a, and 2b [51–53].
The article (2016) and meeting abstract (2014) by
Mitra et al. report that Panbio RDT alone is highly sen-
sitive and cost effective for diagnosis of dengue infec-
tion in their comparative evaluation of performance
and cost-effectiveness of commercially available
immunochromatography-based RDT kits [51, 52]. This
study is not, in fact, a cost-effectiveness analysis and re-
ports a high sensitivity (97%) for Panbio RDT and a cost
of 13.6 USD (reported in the abstract in 2014, 6.90
USD in the article in 2016) which they refer to as being
cost-effective without clearly defining the basis of mea-
surements, i.e. denominator [51, 52]. They compared
four commercially available RDTs [Panbio Dengue Duo
cassette, Standard Diagnostics (SD) Bioline Dengue
Duo, J. Mitra Dengue Day-1 test and Reckon Dengue
IgG/IgM] against composite reference criteria (CRC),
and compared the cost of the tests. The authors con-
ducted this study among stored blood samples from
281 patients who sought care for acute febrile illness at
Christian Medical College (CMC) hospital in Vellore,
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India [52]. The CRC was locally developed by infectious
diseases expert, virologist, epidemiologist, reflecting
WHO guidelines and this was used to identify dengue
cases while lab-confirmed etiology of other cases of
fever was needed to identify non-dengue controls. The
authors measured sensitivity, specificity, and predictive
values of these commercial RDTs in dengue cases and
non-dengue controls. Based on IgM capture positivity
of the four selected RDT kits, Panbio test was found to
have the highest sensitivity, followed by SD Duo (97.7
and 64.3% respectively) [52]. However, specificity was
higher for the Reckon RDT and SD Duo at 99.3 and
96.6%, respectively, compared to Panbio at 87.8%.
Based on NS1 antigen capture assay, none were found
to show satisfactory results in terms of sensitivity, while
specificity was high, around 90% [52]. Therefore, even
though the cost of Panbio test was the highest at 6.90
USD (in 2016) compared to the rest three ranging
Fig. 1 Flow of the literature search in the systematic review
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between 3.29 to 4.27 USD, it was concluded that IgM
assay by Panbio would be the test of choice and a cost-
effective option for diagnosis of acute dengue infection
in endemic settings.
An economic evaluation based on cost-effectiveness
modeling by Lubell et al. (2016) reported that use of a den-
gue RDT is found to be not advantageous, more costly
and less effective, when compared to the common practice
of presumptive treatment with antibiotics prescription
[53]. The authors developed a model to measure the im-
pact and cost-effectiveness of testing for elevated C-
reactive protein (CRP), compared with RDTs for dengue
and scrub typhus in the management of undifferentiated
fever. They used data from 1083 outpatients between 5
and 49 years of age from three provincial hospitals in rural
Laos [53]. A decision tree model was developed to deter-
mine cost effectiveness of different testing approaches for
undifferentiated fever and measure the ability of dengue
and scrub typhus rapid tests, compared with testing for el-
evated CRP, to inform antibiotic treatment as currently
practiced in clinical settings. The authors assumed sensi-
tivity and specificity of a dengue RDT to be 95% and con-
ducted economic evaluation to calculate the median
incremental cost, the number of disability adjusted life
years (DALYs) averted, and incremental cost-effectiveness
ratios (ICER) for each strategy compared to the current
practice of antibiotics prescription. For this, the model
adopted assumptions in sensitivity and specificity of tests,
costs of tests, the cost of a course of antibiotic, duration of
all self-limiting viral infections and treated bacterial infec-
tion, as well as duration of bacterial infections that do not
receive an appropriate treatment, mortality rate, a mean
loss of life-years for a case of death, etc. Another import-
ant parameter in the model was incidence. The authors
used incidence estimates of different pathogens to calcu-
late proportion of patients who were given antibiotics for
bacterial infections and proportion of those given antibi-
otics for viral infections. Furthermore, variable level of in-
cidence between half to double of what was found in the
fever study was applied in the model to test robustness of
model outcomes. The model output reported that a den-
gue RDT is dominated by current practice, with a higher
cost (median incremental cost = $1.5, Crl: 0.5; 3.2) and
fewer numbers of DALYs averted (−0.006 DALYs, CrI:
−0.301; 0.089) on average.
Discussion
The hypothesis behind this review was that prompt detec-
tion of dengue in the early phase of illness using RDTs may
lead to economic benefit in terms of patients’ cost of illness.
The review was from both the point of view of cost effect-
iveness of RDT and the perspective of financial impact of
RDT. We found two studies with different conclusions
[51–53]. Two studies were heterogenous in terms of design
— cost-effectiveness modelling or comparative evaluation
of performance of RDTs. They both took place in
dengue-endemic locations, in India and in Laos, over
different time periods between 2008 and 2013 [51–53].
In both studies, the authors acknowledged limited
generalizability to other populations of febrile patients,
possibly due to specific epidemiological characteristics
of each study area [51–53]. Epidemiological profiles,
such as a varying level of sero-prevalence and likely
high proportion of secondary infections [42], and par-
ticular serotype profiles [54, 55] could affect perform-
ance of RDTs for detection of dengue.
In the comparative evaluation of performance of RDTs,
the authors concluded that Panbio RDT is cost-effective.
Performance of IgM assay by Panbio was the most satisfac-
tory in the diagnosis of acute dengue infection and the cost
of the test was acceptable. This was although the cost based
on the manufacturer’s quoted price in India for Panbio was
the highest at 6.90 USD compared to the rest three: SD,
Reckon and J. Mitra at US$ 4.27, 3.29 and 3.61, respect-
ively. The authors also explored different combinations.
When NS1 antigen capture positivity alone was considered,
all three tests (Panbio is IgM assay only) showed sensitivity
below 30% while specificity was satisfactory, higher than
90% for all three tests. Thus, the authors concluded the
NS1-based test to be unreliable. Also, the authors explored
changes in performance when combined tests were used.
Paired with Panbio RDT, other three RDTs only marginally
increased the sensitivity while combination of Reckon with
any of the three RDTs was found to increase specificity to
higher than 99%. However, such combined testing would
double the cost. Thus, the authors concluded that Panbio
IgM-based RDT alone would be a cost-effective and sensi-
tive option especially during the times of outbreak in
dengue-endemic settings [51].
The main limitation of the study is that the RDT per-
formance was not compared with other standard tests,
such as NS1 or IgM capture based ELISA or RT-PCR.
There are standard ways of laboratory-based confirm-
ation of dengue infection using various assays that are
available. While the authors indicate that using CRC as
case definition is commonly done, such an assessment of
RDT performance may not be most accurate. Also, as
acknowledged by the authors, the study results could
have been affected by cross-reactivity with other flavi-
viruses circulating in the study area [52]. Also, dengue
RDTs are commonly used especially in the areas of high
incidence of dengue [56]. However, when the study mea-
sured prevalence of dengue, the authors found 15.9 to
49.3% of IgG positivity among the samples in the study
and it was comparatively lower than prevalence of IgG
positivity previously measured by other studies. If preva-
lence of dengue or other flaviviruses is lower than what
was previously estimated, then performance of the RDTs
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would have been different in cases of low-level transmis-
sion of dengue or other flaviviruses.
Based on an economic evaluation using cost-
effectiveness modeling, Lubell et al. showed that the a den-
gue RDT would provide little or no advantage in terms of
health outcomes among patients with AFI while resulting
in higher costs than current practice of antibiotics prescrip-
tion [53]. As well as a dengue RDT, they had also modeled
cost-effectiveness of a scrub typhus RDT and CRP test. For
these two, the model showed that there are advantages
over current practice of antibiotics prescription while cost
would increase. There may be limited generalizability of
the model outcomes, due to some of specific assumptions
used in the model for this particular study sample obtained
from Laos. For example, the years of life lost per death was
assumed to be 45 years, based on the median age of outpa-
tients and life expectancy in Laos. For the costs of tests, a
gamma distribution was applied with a mean of $1.5, which
may be lower than the current price of commonly used
RDTs. The study was conducted in an outpatient-sample
where dengue was confirmed in about slightly higher than
10% of the patients. While the study explored how the
model outcomes would change if the incidence of dengue
were to be variable between 50 and 200% of what was
found in the fever study in Laos and found out that still
CRP test would outperform both RDTs for dengue and
scrub typhus, the study does not report how higher inci-
dence of dengue will impact the median incremental cost
and median DALYs averted by using dengue RDTs.
Also, the authors acknowledged limitations due to diag-
nostic uncertainty where multiple pathogens are detected
for some patients whereas some others had no identifiable
pathogen as the cause of illness. Depending on misclassifi-
cation due to diagnostic limitations, there may be changes
in economic benefit of dengue RDTs. Another limitation
of the study was that the model does not consider societal
impact of such viral infections where use of dengue RDTs
may not be immediately cost-effective, but diagnosis based
on dengue RDTs may provide benefit by raising awareness
for signs of severe manifestation of illness or alerting
health authorities of outbreaks for preventive and control
measures, etc.
The authors, qualitatively, report that there would be
improvements to current practice of antibiotics prescrip-
tion whereby a dengue RDT would be used to prevent
antibiotics prescribed to patients with viral infections
[53]. Although not measured, there are long-term bene-
fits of vigilant antibiotics prescription where dengue
RDTs could be used for non-dengue confirmation to
prompt antibiotics prescription, leading to a higher
probability of bacterial infections receiving appropriate
treatment. If these societal impact and long-term indir-
ect benefits were considered in economic evaluation,
dengue RDTs may be associated with higher cost-
effectiveness than what was predicted in the current
model.
The main assumption behind the topic of this review
was the prompt detection of dengue in the early phase of
illness using RDTs leading to economic impact, with both
perspectives of cost-effectiveness and financial benefit.
There are RDTs that detect IgA, IgM or IgG antibodies, as
well as NS1 antigen [39]. Depending on the detection
methods, the utility of these RDTs may be quite different
and there can be variable performance characteristics.
Only the study by Mitra et al. used commercially available
RDTs for comparison, and Lubell et al. conducted a mod-
eling analysis using a hypothetical RDT for dengue with
95% sensitivity and specificity in the model assumption.
With limited evidence, such comparison among different
test methods (or kits) could not be made in this review
[42, 57]. Also, RDT performance could vary depending on
factors such as the type of infection (primary vs. secondary
infection), the time since onset of illness, and the serotype.
It was assumed that the decision to use RDTs and refer to
the test result for diagnosis and to guide clinical manage-
ment would be at discretion of clinicians. Although there
were no data reporting such findings, different RDTs’ vari-
able range of performance and accuracy could lead to mis-
classification in terms of dengue diagnosis. And this could
affect the test performance and lead to bias by under or
over-estimating the economic impact of early detection of
dengue. Limited by data availability and lack of assurance
on the direction of bias, these factors influencing perform-
ance were not considered in this literature review.
With 2.5 billion people at risk, efforts to develop vac-
cine and other preventive tools continue, but dengue re-
mains a substantial burden to the healthcare system and
society in the endemic countries. [7, 58]. The total an-
nual global cost of dengue illness was estimated at
US$8·9 billion and in a large country like Brazil, it is re-
ported that the estimated cost for dengue for the epi-
demic season in the societal perspective would reach as
high as US$ 1212 million after adjusting for under-
reporting [28, 58, 59]. In a study reviewing medical costs
associated with case management for dengue fever pa-
tients in Mexico, real costs for patients, reported to the
Secretariat of Health, were US$33 for outpatients, and
US$491 for inpatients [60]. How burdensome dengue
treatment costs would be to households was shown in a
study conducted in Cambodia where survey results were
compared in households with dengue positive and the
ones with dengue-negative children [61]. On average,
the total cost of lab-confirmed dengue was 31.5 USD
and the total cost per hospitalized dengue case was 40.1
USD [61]. To finance the cost of a febrile illness, 67% of
households incurred an average debt of 23.5 USD [61].
Compared to an average one-week expenditure on food
in Cambodia, about 9.5 US dollars per household, the
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costs of treatment for dengue, whether outpatient or
hospitalized, put enormous financial strain on the house-
hold [61].
Given this burden and financial strain placed by dengue
on the health system, as well as individuals and house-
holds, many of the articles reviewed acknowledge the need
for accurate and simple diagnostic assays for infection in
resource-limited settings in regions of high dengue en-
demicity. However, we have found only two studies with
different conclusions reached: one concluded that Panbio
RDT at 6.90 USD was cost-effective; the other concluded
that a dengue RDT is associated with negative DALYs
averted while resulting in higher costs than current prac-
tice of antibiotics prescription. The two studies differ in
design and findings cannot be directly compared. With no
additional studies that explicitly estimated the cost-
effectiveness of RDTs for dengue other than these two
studies, such assessments must await future studies for
more conclusive evidence. Likewise, any economic impact
of RDT use in clinical settings, for patients, to health sys-
tems, and for particular situations such as outbreaks, re-
mains to be assessed. Such work would guide appropriate
interventions to improve patient management in
resource-limited settings to reduce the burden of dengue.
Conclusions
Existing studies of dengue RDTs are largely epidemiological
and we found two studies which reported quantitative and
qualitative economic impact of their use. However, these
two studies reported different conclusions and there is a
need for new studies to specifically measure economic
impact of dengue RDTs. Such studies would yield greater
understanding of the benefit of RDTs for dengue and hence
could help reduce the costs incurred due to dengue illness.
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